Treatment of Marmoset Intracerebral Hemorrhage with Humanized Anti-HMGB1 mAb

• Published in: Cells (Basel, Switzerland) Vol. 11; no. 19; p. 2970
• Main Authors: Wang, Dengli, Ousaka, Daiki, Qiao, Handong, Wang, Ziyi, Zhao, Kun, Gao, Shangze, Liu, Keyue, Teshigawara, Kiyoshi, Takada, Kenzo, Nishibori, Masahiro
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 23.09.2022; MDPI
• Subjects: 4-Hydroxynonenal; Animals; Antibodies; antibody therapy; Body weight; Body weight loss; Brain injury; Brain research; CD163 antigen; Clinical outcomes; Clinical trials; Cytokines; Dosage and administration; Drug therapy; Edema; Experiments; Females; Haptoglobin; Hematoma; Heme; Hemoglobin; Hemorrhage; HMGB1; HMGB1 protein; Inflammation; Injection; Intracerebral hemorrhage; Intravenous administration; Iron; Kinases; Macrophages; Males; Marmosets; Medical research; Monoclonal antibodies; non-human primate; Proteins; Traumatic brain injury; Japan; United Kingdom > UK; United States > US
• ISSN: 2073-4409; 2073-4409
• DOI: 10.3390/cells11192970

Intracerebral hemorrhage (ICH) is recognized as a severe clinical problem lacking effective treatment. High mobility group box-1 (HMGB1) exhibits inflammatory cytokine-like activity once released into the extracellular space from the nuclei. We previously demonstrated that intravenous injection of rat anti-HMGB1 monoclonal antibody (mAb) remarkably ameliorated brain injury in a rat ICH model. Therefore, we developed a humanized anti-HMGB1 mAb (OKY001) for clinical use. The present study examined whether and how the humanized anti-HMGB1 mAb ameliorates ICH injury in common marmosets. The results show that administration of humanized anti-HMGB1 mAb inhibited HMGB1 release from the brain into plasma, in association with a decrease of 4-hydroxynonenal (4-HNE) accumulation and a decrease in cerebral iron deposition. In addition, humanized anti-HMGB1 mAb treatment resulted in a reduction in brain injury volume at 12 d after ICH induction. Our in vitro experiment showed that recombinant HMGB1 inhibited hemoglobin uptake by macrophages through CD163 in the presence of haptoglobin, suggesting that the release of excess HMGB1 from the brain may induce a delay in hemoglobin scavenging, thereby allowing the toxic effects of hemoglobin, heme, and Fe2+ to persist. Finally, humanized anti-HMGB1 mAb reduced body weight loss and improved behavioral performance after ICH. Taken together, these results suggest that intravenous injection of humanized anti-HMGB1 mAb has potential as a novel therapeutic strategy for ICH.